MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) reported fourth quarter and full-year 2025 financial results and provided updates ...

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent Inc., a global contract development and manufacturing organization (CDMO), have partnered to ...

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients ...

Earnings call Esperion posted its strongest quarter ever, with Q4 revenue up 144% YoY and U.S. net product sales rising 38%. The planned Corstasis acquisition, strong cash position, and imminent U.S.

ADC Therapeutics recently reported its fourth quarter and full-year 2025 financial results, providing an update on the company's achievements in 2025 and its excitement for the future. The company has ...

Ophthalmic research focus grows around glaucoma therapy and device development Webinar spotlight covers BL therapy and ELIOS surgical platform technology Sector discussion expands alongside activity ...

FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total ...

BALTIMORE, March 11, 2026 /PRNewswire/ -- Children's Milestone, a provider of behavioral health services, is emphasizing the importance of early identification and intervention for children with ...

Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today's conference call will be recorded. I would now like to hand the conference over to ...

Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q4 2025 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Nicole Riley, Head of Investor ...